Abstract: The present invention relates generally to pharmaceutical dosage forms comprising: an absorption window active agent; a controlled release component comprising enteric-coated controlled release beads, wherein the enteric-coated release beads comprise at least two pH-sensitive polymer layers. The controlled-release dosage forms provide good bioavailability of absorption window active agents.

Abstract: The present invention relates to dosage forms of a combination of carbidopa and levodopa comprising both immediate release and controlled release components for the treatment of ailments associated with depleted amounts of dopamine in a patient's brain tissue.

Abstract: The present invention relates generally to pharmaceutical dosage forms comprising: an absorption window active agent; a controlled release component comprising enteric-coated controlled release beads, wherein the enteric-coated release beads comprise at least two pH-sensitive polymer layers. The controlled-release dosage forms provide good bioavailability of absorption window active agents.

Abstract: The present invention relates to pharmaceutical dosage forms of a combination of carbidopa and levodopa comprising both immediate release and controlled release components for the treatment of ailments associated with depleted amounts of dopamine in a patient's brain tissue, which dosage forms display no food effect or at least substantially avoid the food effect, and a related method of treatment for a patient in which the bioavailability of levodopa under non-fasting conditions is equivalent to the bioavailability under fasting conditions.

Abstract: The present invention relates generally to pharmaceutical dosage forms having immediate release and controlled release properties that contain a ?-aminobutyric acid (GABAB) receptor agonist, e.g., baclofen, for the treatment of medical conditions, which includes spasms, cramping, and tightness of muscles, associated with ailments such as multiple sclerosis or certain spinal injuries.

Abstract: The present invention relates generally to pharmaceutical dosage forms having controlled release properties that contain a ?-aminobutyric acid (GABAB) receptor agonist, e.g., baclofen, for the treatment of medical conditions, which includes spasms, cramping, and tightness of muscles, associated with ailments such as multiple sclerosis or certain spinal injuries.

Abstract: The present invention relates generally to pharmaceutical dosage forms having immediate release and controlled release properties that contain a ?-aminobutyric acid (GABAB) receptor agonist, e.g., baclofen, for the treatment of medical conditions, which includes spasms, cramping, and tightness of muscles, associated with ailments such as multiple sclerosis or certain spinal injuries.

Abstract: The present invention relates generally to pharmaceutical dosage forms having immediate release and controlled release properties that contain a ?-aminobutyric acid (GABAB) receptor agonist, e.g., baclofen, for the treatment of medical conditions, which includes spasms, cramping, and tightness of muscles, associated with ailments such as multiple sclerosis or certain spinal injuries.

Abstract: The present invention relates generally to pharmaceutical dosage forms having immediate release and controlled release properties that contain a ?-aminobutyric acid (GABAB) receptor agonist, e.g., baclofen, for the treatment of medical conditions, which includes spasms, cramping, and tightness of muscles, associated with ailments such as multiple sclerosis or certain spinal injuries.

Abstract: The present invention relates generally to pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase (AAAD) inhibitor (such as carbidopa), levodopa, and optionally a cathecol-O-methyltransferase (COMT) inhibitor, for the treatment of medical conditions associated with reduced dopamine levels in a patient's brain.

Abstract: The present invention relates to dosage forms of a combination of carbidopa and levodopa comprising both immediate release and controlled release components for the treatment of ailments associated with depleted amounts of dopamine in a patient's brain tissue.

Abstract: Dosage forms containing both immediate release and sustained release components for the treatment of ailments associated with depleted amounts of dopamine in brain tissue of a patient. The dosage forms contain a combination of carbidopa and levodopa.

Abstract: A method of producing a composite image on an image recording medium from first and second component images, represented by digital image data, comprising the steps of converting the digital image data of each image into electromagnetic radiation image data; and forming the composite image by successively exposing the recording medium to the electromagnetic radiation image data of the first and second images so that the images are created on the medium in overlapping relationship to form a join region. The medium is doubly exposed, first by the image data of the first image and then by the image data of the second image. The intensity of the electromagnetic radiation representing the first image is progressively ramped off in the join region and the intensity of the electromagnetic radiation representing the second image is progressively ramped on in the join region.